Interleukin-6 receptor genetic variation and tocilizumab treatment response to COVID-19
Ammar Ali Almarzooq
doi: https://doi.org/10.1101/2021.04.24.21256047
Ammar Ali Almarzooq
1Galore Consultancy, Flat 12, Building 144, Road 336, Block 314, Manama, Bahrain
Posted April 27, 2021.
Interleukin-6 receptor genetic variation and tocilizumab treatment response to COVID-19
Ammar Ali Almarzooq
medRxiv 2021.04.24.21256047; doi: https://doi.org/10.1101/2021.04.24.21256047
Subject Area
Subject Areas
- Addiction Medicine (317)
- Allergy and Immunology (621)
- Anesthesia (162)
- Cardiovascular Medicine (2318)
- Dermatology (205)
- Emergency Medicine (373)
- Epidemiology (11653)
- Forensic Medicine (10)
- Gastroenterology (687)
- Genetic and Genomic Medicine (3655)
- Geriatric Medicine (344)
- Health Economics (625)
- Health Informatics (2340)
- Health Policy (922)
- Hematology (337)
- HIV/AIDS (765)
- Medical Education (362)
- Medical Ethics (102)
- Nephrology (394)
- Neurology (3406)
- Nursing (193)
- Nutrition (512)
- Oncology (1787)
- Ophthalmology (529)
- Orthopedics (212)
- Otolaryngology (284)
- Pain Medicine (227)
- Palliative Medicine (66)
- Pathology (442)
- Pediatrics (1014)
- Primary Care Research (411)
- Public and Global Health (6046)
- Radiology and Imaging (1243)
- Respiratory Medicine (816)
- Rheumatology (373)
- Sports Medicine (319)
- Surgery (391)
- Toxicology (50)
- Transplantation (171)
- Urology (144)